Literature DB >> 9149696

Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study.

C J Murray1, A D Lopez.   

Abstract

BACKGROUND: Information on non-fatal health outcomes of disease and injury has been largely neglected in health planning because of the conceptual and definitional complexity of measuring morbidity and disability in populations. One of our major objectives was to quantify disability for inclusion in health policy debates. We analysed these health outcomes in terms of disability-free life expectancy (DFLE) and disability-adjusted life expectancy (DALE).
METHODS: Published and unpublished data were systematically reviewed to estimate the incidence, prevalence, and duration of 483 disabling sequelae of 107 diseases and injuries. To ensure internal consistency of these estimates, a software programme (DISMOD) was applied many times until consistent parameters were identified. The severity of disability, on a scale of 0 (perfect health) to 1 (death), was measured in a deliberate manner by the person-trade-off method. Spearman's and Pearson's correlation coefficients were used to measure disability weights among groups. Prevalence of seven classes of disability was back-calculated from the distribution of each disabling sequela across disabilities. Prevalence for each class of disability for different age-sex groups was used to calculate seven forms of DFLE and DALE based on Sullivan's method.
FINDINGS: Prevalence of most disability classes is highest in sub-Saharan Africa and lowest in established market economies. Low-severity disabilities (class I and class II) are the most common. The expectation at birth of class I disability ranges from 6.5 years in established market economies to 14.7 years in sub-Saharan Africa, and for class II disabilities, from 8.5-18.4 years. DFLE varies significantly among regions: DFLE for class I disabilities at birth ranges from 9.9 years in sub-Saharan Africa to 47.7 years in established market economies for females and DFLE for class V disabilities ranges from 43.4 years for men in sub-Saharan Africa to 74.8 years for women in established market economies. The proportion of expected life span at birth lived with disability adjusted for severity, varies from about 8% in established market economies to 15% in sub-Saharan Africa, with little difference between men and women. In high-income regions, nearly 90% of expected disability is due to non-communicable diseases and most of the remainder to injuries. In poorer regions, almost half of expected disability is due to communicable diseases and injuries.
INTERPRETATION: The higher proportion of lifespan spent disabled in high-mortality populations is consistent with the compression of morbidity hypothesis. The threshold definition of disability used substantially affects the results of DFLE, DALE, which incorporates severity weights for disabilities, is a useful summary measure of the burden of disability and mortality.

Entities:  

Keywords:  Demographic Factors; Developed Countries; Developing Countries; Diseases; Length Of Life; Life Expectancy; Measurement; Morbidity; Mortality; Population; Population Dynamics; Prevalence; Research Methodology; Research Report; World

Mesh:

Year:  1997        PMID: 9149696     DOI: 10.1016/S0140-6736(96)07494-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  84 in total

1.  The expiry date of man: a synthesis of evolutionary biology and public health.

Authors:  L Bonneux; J J Barendregt; P J Van der Maas
Journal:  J Epidemiol Community Health       Date:  1998-10       Impact factor: 3.710

2.  A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group.

Authors:  J M Melse; M L Essink-Bot; P G Kramers; N Hoeymans
Journal:  Am J Public Health       Date:  2000-08       Impact factor: 9.308

3.  Estimating the "avoidable" burden of disease by Disability Adjusted Life Years (DALYs).

Authors:  S Hollinghurst; G Bevan; C Bowie
Journal:  Health Care Manag Sci       Date:  2000-01

Review 4.  Effects and safety of periconceptional folate supplementation for preventing birth defects.

Authors:  Luz Maria De-Regil; Ana C Fernández-Gaxiola; Therese Dowswell; Juan Pablo Peña-Rosas
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

5.  Treatment of major depressive disorder in children and adolescents.

Authors:  Paul Ramchandani
Journal:  BMJ       Date:  2004-01-03

6.  Why treat depression differently from other medical problems?

Authors:  Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

7.  Decomposition of differences in health expectancy by cause.

Authors:  Wilma J Nusselder; Caspar W Looman
Journal:  Demography       Date:  2004-05

Review 8.  Regional research priorities in brain and nervous system disorders.

Authors:  Vijayalakshmi Ravindranath; Hoang-Minh Dang; Rodolfo G Goya; Hader Mansour; Vishwajit L Nimgaonkar; Vivienne Ann Russell; Yu Xin
Journal:  Nature       Date:  2015-11-19       Impact factor: 49.962

9.  Residual cardiovascular risk in secondary prevention.

Authors:  Alberto Zambon
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

10.  Carriers of a common variant in the dopamine transporter gene have greater dementia risk, cognitive decline, and faster ventricular expansion.

Authors:  Florence F Roussotte; Boris A Gutman; Derrek P Hibar; Sarah K Madsen; Katherine L Narr; Paul M Thompson
Journal:  Alzheimers Dement       Date:  2014-12-10       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.